Skip to Main Content

Yale SPORE in Lung Cancer News

Navigating the Evolving Landscape of EGFR-Mutated NSCLC

Combination chemotherapy has long been a mainstay of cancer treatment, although early mechanism-based therapies showed little promise. More than 50 years later, this foundational principle — in which biologic rationale is used to guide the choice of treatment combinations — is being applied to the leading cause of cancer-related deaths: lung cancer. Today, genomic profiling, targeted agents, and strategies informed by resistance mechanisms are reshaping care for epithelial growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC).

Source: New England Journal of Medicine (Yale's Dr. Roy Herbst)
Read more
Get RSS Feed